READ-ONLY DIGITIZATION RESULT
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.
Nat Commun · 2026-Mar-14 · PMID 41826281
Panel C质量警告待 EXE 对齐验证
Progression-free survival
Fig. 4. Progression-free survival by PD-L1 expression. Kaplan–Meier estimate in subgroups of PD-L1 CPS1 ( A ), PD-L1 CPS≥1 ( B ), PD-L1 CPS≥10 ( C ), and subgroup analysis ( D ). Source data are provided as a Source data file.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
| Curve | 序号 | X (norm) | Y (norm) | X (real) | Y (real) | X (pixel) | Y (pixel) |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 0.0000 | 0.9593 | 0.0000 | 100.7317 | 63 | 7 |
| 1 | 2 | 0.0807 | 0.9350 | 2.8889 | 98.1707 | 89 | 10 |
| 1 | 3 | 0.0839 | 0.9350 | 3.0000 | 98.1707 | 90 | 10 |
| 1 | 4 | 0.0870 | 0.9350 | 3.1111 | 98.1707 | 91 | 10 |
| 1 | 5 | 0.0901 | 0.9350 | 3.2222 | 98.1707 | 92 | 10 |
| 1 | 6 | 0.0932 | 0.9350 | 3.3333 | 98.1707 | 93 | 10 |
| 1 | 7 | 0.0963 | 0.9350 | 3.4444 | 98.1707 | 94 | 10 |
| 1 | 8 | 0.0994 | 0.9350 | 3.5556 | 98.1707 | 95 | 10 |
| 1 | 9 | 0.1025 | 0.9350 | 3.6667 | 98.1707 | 96 | 10 |
| 1 | 10 | 0.1056 | 0.9350 | 3.7778 | 98.1707 | 97 | 10 |
| 1 | 11 | 0.1087 | 0.9350 | 3.8889 | 98.1707 | 98 | 10 |
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T16:51:01+00:00 |